542 related articles for article (PubMed ID: 17702184)
21. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
Sasaki T; Komiya A; Suzuki H; Shimbo M; Ueda T; Akakura K; Ichikawa T
Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
[TBL] [Abstract][Full Text] [Related]
22. Relapsed prostate cancer with neuroendocrine differentiation and high serum levels of carcinoembryonic antigen without elevation of prostrate-specific antigen: a case report.
Kinebuchi Y; Noguchi W; Irie K; Nakayama T; Kato H; Nishizawa O
Int J Urol; 2007 Feb; 14(2):147-9. PubMed ID: 17302572
[TBL] [Abstract][Full Text] [Related]
23. [Prostatic cancer in a young adult: a report of 2 cases].
Sasaki H; Miki J; Hasegawa T; Hasegawa N; Ikemoto I; Ohishi Y
Hinyokika Kiyo; 2004 Jan; 50(1):57-9. PubMed ID: 15032019
[TBL] [Abstract][Full Text] [Related]
24. [Prostate cancer with high serum level of CEA and CA19-9: a case report].
Momma T; Kimura S; Saito S; Onoda N
Hinyokika Kiyo; 1998 Mar; 44(3):187-91. PubMed ID: 9589883
[TBL] [Abstract][Full Text] [Related]
25. [A case of ductal carcinoma of the prostate after transurethral resection of prostate].
Izumi K; Kanno H; Umemoto S; Hasumi H; Osada Y; Ota J; Tsuchiya F; Ogino I; Harada M
Hinyokika Kiyo; 2007 May; 53(5):315-8. PubMed ID: 17561717
[TBL] [Abstract][Full Text] [Related]
26. The chromogranin-A (CgA) in prostate cancer.
Ranno S; Motta M; Rampello E; Risino C; Bennati E; Malaguarnera M
Arch Gerontol Geriatr; 2006; 43(1):117-26. PubMed ID: 16280180
[TBL] [Abstract][Full Text] [Related]
27. [Composite carcinoma of the prostate combining a small cell carcinoma and an adenocarcinoma. Apropos of a case].
Kantelip B; Viallard JL; Costes-Chalret N; Francannet P
Ann Pathol; 1989; 9(2):121-5. PubMed ID: 2544191
[TBL] [Abstract][Full Text] [Related]
28. [Prostate cancer detected from pleural effusion: two case reports].
Masue T; Hattori S; Takagi K; Uno M; Komeda H; Fujimoto Y
Hinyokika Kiyo; 2008 Aug; 54(8):565-8. PubMed ID: 18788449
[TBL] [Abstract][Full Text] [Related]
29. Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: a case report and short literature review.
Yashi M; Terauchi F; Nukui A; Ochi M; Yuzawa M; Hara Y; Morita T
Urol Oncol; 2006; 24(4):313-7. PubMed ID: 16818183
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical staining and serotest markers during development of a sarcomatoid and small cell prostate tumor.
Frković-Grazio S; Kraljić I; Trnski D; Tarle M
Anticancer Res; 1994; 14(5B):2151-6. PubMed ID: 7840515
[TBL] [Abstract][Full Text] [Related]
31. [Prostate cancer with penile metastasis: a case report].
Sawada A; Segawa T; Nakanishi S; Kinoshita H; Yamamoto S; Kamoto T; Ogawa O
Hinyokika Kiyo; 2005 Nov; 51(11):771-3. PubMed ID: 16363713
[TBL] [Abstract][Full Text] [Related]
32. [Prostatic cancer with cystic formation: a case report].
Takayama H; Arai Y; Meguro N; Maeda O; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T
Hinyokika Kiyo; 1996 Dec; 42(12):977-80. PubMed ID: 9013236
[TBL] [Abstract][Full Text] [Related]
33. [Clinicopathological characterization of prostatic small cell carcinoma: a case report and review of the literature].
Wei ZF; Xu H; Wang H; Wei W; Cheng W; Zhou WQ; Ge JP; Zhang ZY; Gao JP; Yin HL
Zhonghua Nan Ke Xue; 2009 Sep; 15(9):829-32. PubMed ID: 19947569
[TBL] [Abstract][Full Text] [Related]
34. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study.
Turbat-Herrera EA; Herrera GA; Gore I; Lott RL; Grizzle WE; Bonnin JM
Arch Pathol Lab Med; 1988 Nov; 112(11):1100-5. PubMed ID: 2460064
[TBL] [Abstract][Full Text] [Related]
35. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Masue N; Hasegawa Y
Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
[TBL] [Abstract][Full Text] [Related]
36. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Slovin SF
Nat Clin Pract Oncol; 2007 Sep; 4(9):551-4. PubMed ID: 17728713
[TBL] [Abstract][Full Text] [Related]
37. Secretagogin is a new neuroendocrine marker in the human prostate.
Adolf K; Wagner L; Bergh A; Stattin P; Ottosen P; Borre M; Birkenkamp-Demtröder K; Orntoft TF; Tørring N
Prostate; 2007 Apr; 67(5):472-84. PubMed ID: 17285592
[TBL] [Abstract][Full Text] [Related]
38. [Small cell carcinoma of the prostate: an autopsy case report].
Shimizu N; Miyatake R; Esa A; Ishikawa Y
Hinyokika Kiyo; 2005 Jun; 51(6):399-402. PubMed ID: 16050480
[TBL] [Abstract][Full Text] [Related]
39. Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients.
Tarle M; Ahel MZ; Kovacić K
Anticancer Res; 2002; 22(4):2525-9. PubMed ID: 12174956
[TBL] [Abstract][Full Text] [Related]
40. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
